Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efanesoctocog alfa - Bioverativ/Sanofi

Next Previous
Drug Profile

Efanesoctocog alfa - Bioverativ/Sanofi

Alternative Names: Altuviiio; Antihemophilic factor (recombinant) - Bioverativ/Sanofi; BIVV-001; Factor VIII recombinant - Bioverativ/Sanofi; Fc-VWF-XTEN fusion protein-ehtl; Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion protein; rFVIIIFc-VWF-XTEN; rFVIIIFc-XTEN-vWF; XTENylated Factor VIII

Latest Information Update: 11 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amunix
  • Developer Amunix; Bioverativ; Sanofi; Swedish Orphan Biovitrum
  • Class Antihaemorrhagics; Blood coagulation factors; Recombinant fusion proteins
  • Mechanism of Action Factor VIII replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia A
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Haemophilia A
  • Phase I Von Willebrand disease

Most Recent Events

  • 06 Mar 2024 Swedish Orphan Biovitrum and Syneos Health initiates a phase IIIb FREEDOM trial for Haemophilia A (Treatment experienced, In adolescents, In adults, In elderly) in Austria, Belgium, Croatia, Czech Republic, France, Germany, Greece, Ireland, Netherlands, Norway, Slovenia, Spain, Sweden, United Kingdom (IV) (NCT05817812)
  • 31 Dec 2023 Preregistration for Haemophilia A in Saudi Arabia (IV) prior to December 2023
  • 31 Dec 2023 Launched for Haemophilia A (In adolescents, In children, In the elderly, Treatment-experienced, In adults) in Japan (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top